Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Tharos who wrote (8129)	12/27/1998 2:15:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

check out cystic fibrosis article. chestnet.org

To: Tharos who wrote (8129)	1/14/1999 6:48:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 17367

psoriasis Today ICOS put out their latest PR, I guess they talk today at 11:30 PST... ICOS Announces Erectile Dysfunction Results, Initiation of Psoriasis Trial and a New Clinical Candidate biz.yahoo.com In disease models IC14 blocks the cytokine cascade induced by endotoxin and also prevents a severe drop in blood pressure that precedes multiple organ dysfunction. A Phase 1 clinical trial in Europe is enrolling approximately 20 normal volunteers in a single dose setting to compare IC14 to placebo. Anyway, I did not know ICOS had a lead for psoriasis, much less a phase I going... recap.com fyi...my darts for psoriasis happen to be on xoma and btrn, but only indirectly...really I have xoma for pediatric meningococcemia...and btrn for GvHD. If somebody is dying to key in a primer on CD14, I'd love to hear some thoughts from a science guy. --Mike